Neil Minkoff, MD; Maria Lopes, MD, MS; Nancy Ross, PharmD, BCACP, MSCS, CSP; Thomas Leist, MD; and Darin Okuda, MD explore opportunities for improving long-term patient outcomes in MS through earlier use of high efficacy therapies, including those of clinical and payer consideration.
EP. 1: Overview of Multiple Sclerosis
A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.
Maria Lopes, MD, MS discusses payer considerations and challenges in MS treatment management with the ongoing paradigm shift toward early high-efficacy treatment.
EP. 8: Risks of Undertreatment in MS and Impact of Early High Efficacy Therapy
Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.
EP. 11: High Efficacy Therapies in MS: Ocrelizumab, Ofatumumab, and Cladribine
Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.
EP. 14: Future of MS Management
Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.